patholog
respiratori
system
lung
infect
chronic
inflammatori
lung
diseas
lung
cancer
among
lead
caus
morbid
mortal
kill
one
six
peopl
worldwid
develop
effect
treatment
hinder
lack
preclin
model
human
lung
captur
diseas
complex
highli
heterogen
diseas
phenotyp
pharmacokinet
pharmacodynam
observ
patient
merger
two
novel
technolog
organsonchip
human
stem
cell
engin
potenti
deliv
urgent
need
model
organsonchip
microengin
bioinspir
tissu
system
recapitul
mechanochem
environ
physiolog
function
human
organ
concurr
advanc
gener
differenti
human
stem
cell
promis
renew
suppli
patientspecif
cell
person
precis
medicin
discuss
challeng
model
human
lung
pathophysiolog
vitro
evalu
past
current
model
includ
organsonchip
review
current
statu
lung
tissu
model
use
human
pluripot
stem
cell
explor
depth
stemcel
base
lungonchip
may
advanc
diseas
model
drug
test
summar
practic
consider
design
lungonchip
academ
industri
applic
lung
constitut
largest
tissu
interfac
human
bodi
environ
expos
averag
seven
liter
inhal
air
per
minut
lung
direct
contact
countless
noxiou
particl
viral
bacteri
pathogen
hazard
chemic
toxic
gase
formul
green
et
al
day
surfac
larg
tenni
court
expos
volum
air
contamin
would
fill
swim
pool
surprisingli
lung
suscept
numer
deadli
acut
chronic
condit
constitut
immens
global
health
burden
inde
respiratori
diseas
directli
respons
one
six
death
worldwid
chronic
respiratori
condit
affect
one
billion
peopl
worldwid
europ
alon
total
cost
respiratori
diseas
amount
billion
annual
among
respiratori
diseas
five
account
major
morbid
mortal
worldwid
chronic
obstruct
pulmonari
diseas
copd
asthma
acut
respiratori
infect
tuberculosi
lung
cancer
recent
report
suggest
onset
aggrav
respiratori
diseas
caus
inand
outdoor
air
pollut
respons
million
death
annual
number
like
increas
even
futur
therefor
imper
develop
new
therapeut
strategi
lung
diseas
requir
new
tool
better
studi
respiratori
diseas
understand
underli
mechan
studi
lung
diseas
pathogenesi
drug
efficaci
well
inhal
toxicolog
necessit
physiolog
relev
model
human
lung
tissu
anim
especi
rodent
provid
semin
insight
lung
physiolog
pathophysiolog
limit
recapitul
develop
structur
diseas
symptom
respons
human
respiratori
system
provid
strong
rational
develop
investig
human
vitro
lung
model
diseas
model
drug
discoveri
drug
test
instanc
time
lung
development
event
differ
markedli
mice
human
prenat
saccular
stage
alveolar
sac
distinguish
alveolar
cell
type
form
surfact
secret
begin
take
place
rel
earlier
postnat
differenti
immatur
saccul
continu
rel
longer
time
human
compar
mice
differ
pace
lung
develop
result
greater
degre
branch
complex
human
distal
lung
structur
includ
respiratori
bronchiol
alveolar
duct
associ
alveoli
cellular
composit
also
differ
mous
human
lung
exampl
mous
airway
mucusproduc
goblet
cell
rare
secretori
club
cell
formerli
known
clara
cell
abund
wherea
opposit
appli
human
airway
mani
gene
mutat
induc
differ
respiratori
symptom
mice
compar
human
rodent
remain
main
anim
model
preclin
studi
nonrod
speci
guinea
pig
dog
sheep
pig
nonhuman
primat
close
mimic
human
lung
physiolog
also
use
preclin
studi
howev
ethic
financi
issu
well
nonavail
speciesspecif
reagent
often
preclud
use
routin
experiment
taken
togeth
limit
demonstr
anim
imperfect
model
rang
human
lung
diseas
drug
treatment
necessit
need
humanspecif
preclin
model
lung
standard
cultur
cancer
immort
cell
line
still
repres
common
altern
anim
model
studi
tissu
pathophysiolog
respons
pharmacolog
agent
great
advantag
cell
line
eas
use
highthroughput
experi
cloud
limit
physiolog
relev
clinic
predict
past
year
advanc
tissu
engin
soft
lithographi
techniqu
converg
give
rise
organsonchip
miniatur
microengin
cell
cultur
system
recreat
key
function
microenvironment
featur
human
organ
vitro
importantli
idea
rebuild
entir
human
lung
intric
architectur
far
remain
technic
feasibl
would
also
greatli
complic
experiment
manipul
analysi
interpret
engin
system
rather
promis
great
benefit
organsonchip
lie
abil
recreat
welldefin
function
unit
lung
alveolar
epitheliumblood
capillari
interfac
mucociliari
barrier
airway
specif
lungonchip
model
use
isol
amplifi
systemat
combin
specif
cellular
acellular
compon
tissu
dissect
interact
well
individu
role
health
diseas
process
concurr
advanc
organsonchip
technolog
field
development
biolog
made
tremend
progress
toward
effici
cultur
differenti
stem
cellderiv
human
lung
tissu
form
static
cultur
organoid
stem
cell
technolog
enabl
precis
model
virtual
human
tissu
longterm
cultur
patientderiv
cell
organsonchip
provid
cell
microenviron
biomechan
forc
vascular
perfus
circul
immun
cell
tissu
relev
cytoarchitectur
sampl
capabl
organoid
lack
therefor
possibl
combin
technolog
help
studi
human
lung
develop
pathophysiolog
respons
inhal
toxic
evalu
drug
pharmacodynam
pharmacokinet
pkpd
discov
new
diagnost
therapeut
purpos
review
provid
comprehens
survey
exist
stateoftheart
organsonchip
system
model
human
lung
tissu
envis
innov
technolog
converg
field
lung
stem
cell
establish
highli
relev
model
lung
develop
respiratori
diseas
drug
pkpd
difficulti
vitro
tissu
model
lie
challeng
identifi
faith
recapitul
essenti
structur
function
element
human
tissu
govern
healthi
patholog
organ
respons
especi
case
complex
organ
human
lung
challeng
increas
incomplet
understand
organ
morpholog
physiolog
exemplifi
unclear
role
sever
differ
resid
cell
play
lung
homeostasi
lung
exert
essenti
seemingli
simpl
vital
function
provid
constant
suppli
oxygen
remov
co
ga
exchang
inhal
air
circul
blood
lung
morpholog
complex
consist
distinct
unit
specif
physiolog
role
unit
includ
region
section
defin
respect
cellular
composit
function
trachea
bronchi
bronchiol
small
airway
alveoli
air
sac
stromal
connect
tissu
blood
vessel
hematopoiet
lymphoid
tissu
function
unit
epitheli
mesenchym
trophic
unit
emtu
alveolarcapillari
interfac
fig
togeth
unit
build
organ
architectur
enabl
process
ga
exchang
specif
inhal
air
enter
respiratori
tract
nasal
oral
passag
flow
conduct
airway
reach
distal
airway
alveoli
conduct
airway
compos
trachea
divid
bronchi
bronchiol
bronchiol
lead
alveoli
constitut
lung
surfac
area
enabl
ga
exchang
circul
blood
conduct
airway
line
highli
special
cell
includ
ciliat
cell
mucu
produc
cell
call
goblet
cell
club
cell
underli
basal
cell
act
progenitor
rel
proport
cell
depend
locat
respiratori
tract
instanc
club
cell
almost
nonexist
upper
airway
line
constitut
larg
part
termin
respiratori
bronchiol
cell
popul
similarli
goblet
cell
account
epitheli
cell
larg
airway
almost
absent
termin
respiratori
bronchiol
characterist
cell
distribut
alter
chronic
diseas
exampl
increas
goblet
cell
number
airway
line
observ
patient
obstruct
respiratori
diseas
asthma
copd
distal
respiratori
part
lung
contain
averag
million
pulmonari
alveoli
constitut
thin
flat
nondivid
alveolar
type
ati
cell
enabl
ga
exchang
small
cuboid
alveolar
type
atii
cell
secret
pulmonari
surfact
divid
differenti
replac
damag
alveolar
cell
addit
human
lung
home
numer
resid
circul
immun
cell
includ
macrophag
innat
lymphoid
cell
mast
cell
lymphocyt
eosinophil
neutrophil
contribut
protect
pathogen
noxiou
particl
continu
enter
lung
fig
cell
popul
divers
locat
human
lung
correspond
onchip
model
onchip
model
cell
origin
indic
l
human
cell
line
p
humanderiv
primari
cell
submucosa
surround
conduct
respiratori
airway
epithelium
includ
airway
smooth
muscl
cell
fibroblast
myofibroblast
neural
cell
play
major
role
health
diseas
submucos
cell
also
play
critic
role
mani
respiratori
diseas
instanc
secret
proinflammatori
mediat
hyperrespons
extern
stimuli
airway
smooth
muscl
cell
contribut
tissu
inflamm
lead
bronchoconstrict
airflow
obstruct
asthma
similarli
uncontrol
activ
lung
fibroblast
play
central
role
develop
pulmonari
fibrosi
submucosa
also
harbor
network
blood
lymphat
vessel
compris
endotheli
cell
pericyt
help
recruit
circul
immun
cell
inflammatori
respons
henc
human
lung
complex
tissu
compris
numer
popul
cell
interact
depend
grow
function
properli
high
divers
cell
type
number
function
tissu
morpholog
among
differ
lung
region
diseas
state
essenti
paramet
consid
design
vitro
model
human
lung
preclud
onemodelfitsal
approach
instead
appropri
model
depend
experiment
question
one
wish
answer
goal
recapitul
key
morpholog
function
featur
organ
unit
specif
might
requir
spatiotempor
interact
differ
cell
type
involv
function
pathophysiolog
interest
effect
strategi
initi
creat
simpl
well
character
base
model
increas
complex
ad
cellular
compon
one
one
order
reveal
individu
contribut
given
technic
ethic
difficulti
use
real
human
organ
carri
research
scientist
larg
reli
simpler
smaller
surrog
model
gain
insight
human
physiolog
pathophysiolog
model
human
diseas
gener
lung
diseas
particular
larg
depend
immort
cell
line
primari
cell
combin
one
cell
type
cultur
static
environ
anim
model
fig
howev
cell
monolay
easi
cheap
use
amen
high
throughput
studi
replic
function
mani
tissuespecif
differenti
cell
type
faith
predict
vivo
tissu
function
drug
effect
observ
nativ
human
organ
hand
although
anim
model
provid
access
nativ
tissu
inde
use
model
human
diseas
assess
efficaci
therapeut
number
tissu
organ
often
poor
predictor
clinic
success
due
speciesspeci
differ
mechan
action
toxic
drug
instanc
failur
report
phase
iiiii
clinic
trial
test
distinct
therapeut
anticanc
vaccin
due
elev
level
circul
immunosuppress
cytokin
variou
immunolog
checkpoint
human
may
present
rodent
lung
specif
studi
equal
suffer
limit
overreli
anim
model
complex
human
respiratori
diseas
asthma
contribut
lack
new
efficaci
treatment
despit
huge
research
effort
anim
model
long
record
fail
predict
clinic
efficaci
novel
therapi
human
also
true
sever
respiratori
diseas
includ
cystic
fibrosi
mutat
cystic
fibrosi
transmembran
conduct
regul
cftr
common
genet
caus
human
cystic
fibrosi
howev
mice
mutat
respiratori
abnorm
also
investig
human
respiratori
infect
hinder
lack
human
pathogenspecif
receptor
anim
instanc
major
rhinoviru
type
use
human
intercellular
adhes
molecul
entri
receptor
bind
murin
form
preclud
infect
mous
airway
cell
although
transgen
mous
model
express
human
recent
develop
anim
model
often
also
permiss
replic
human
virus
util
anim
studi
human
chronic
diseas
asthma
develop
therapeut
also
controversi
anim
model
natur
exhibit
asthma
diseas
phenotyp
observ
human
limit
clinic
predict
valu
tradit
cell
cultur
anim
model
motiv
develop
complex
human
vitro
model
incorpor
multipl
type
differenti
cell
involv
cell
pattern
order
repres
morpholog
function
human
organ
three
dimension
cell
cultur
usual
reli
bioinspir
scaffold
made
extracellular
matrix
ecm
synthet
polym
well
specif
growth
factor
cocultur
mesenchym
cell
induc
cell
polar
differenti
cellular
structur
resembl
vivo
tissu
morpholog
function
grown
ecm
hydrogel
cell
selfassembl
cellular
cluster
known
spheroid
organoid
contain
multipl
cell
type
resembl
organ
tissu
architectur
recapitul
specif
organ
function
lung
organoid
deriv
human
primari
lung
tissu
embryon
stem
cell
esc
induc
pluripot
stem
cell
ipsc
also
refer
tracheospher
bronchospher
pneumospher
alveolospher
success
employ
studi
lung
develop
pathophysiolog
nonetheless
also
limit
organoid
lack
nativ
organ
microenviron
appropri
cytoarchitectur
often
essenti
diseas
develop
tissu
growth
repair
anoth
drawback
organoid
cultur
analysi
stimul
enclos
cell
particularli
measur
transmembran
transport
activ
evalu
transport
metabol
drug
across
cell
layer
quantifi
releas
inflammatori
mediat
newli
form
virion
often
preclud
difficulti
access
sampl
lumin
content
also
expos
organoid
uniform
drug
concentr
may
hamper
slow
diffus
interfer
ecm
hydrogel
technic
difficulti
microinject
lumin
space
addit
organoid
usual
lack
tissuetissu
interfac
interfac
vascular
endothelium
surround
stroma
parenchym
cell
essenti
morpholog
function
virtual
organ
final
expos
epithelia
airborn
substanc
mimic
environment
exposur
inhal
drug
deliveri
readili
feasibl
organoid
cultur
possibl
break
organoid
therebi
expos
apic
side
airborn
substanc
mechan
forc
use
process
eg
rapid
pipet
sudden
chang
media
composit
may
caus
cellular
stress
therefor
alter
respons
model
human
airway
epithelium
base
air
liquid
interfac
cultur
primari
epitheli
cell
transwel
insert
also
shown
close
mimic
gene
express
signatur
human
airway
epithelium
vivo
recapitul
sever
hallmark
human
airway
epithelium
vivo
lead
semin
insight
numer
biolog
process
lung
develop
pathophysiolog
howev
organoid
model
typic
lack
physiolog
fluid
solid
mechan
cue
includ
shear
flow
tensil
compress
stress
cell
experi
vivo
absenc
fluid
flow
also
prevent
perfus
cultur
cell
circul
blood
immun
cell
limit
model
inflammatori
respons
infect
drug
though
rel
novel
yet
familiar
investig
emerg
field
organsonchip
promis
overcom
limit
tradit
vitro
model
system
offer
microengin
featur
dynam
stress
microscal
flow
thu
combin
best
attribut
stem
cell
assay
organsonchip
technolog
might
enabl
design
power
vitro
model
human
lung
recent
advanc
microfabr
tissu
engin
made
possibl
creat
organsonchip
ie
continu
perfus
microchannel
line
live
human
cell
design
reconstitut
key
function
microenvironment
featur
whole
organ
includ
tissuetissu
interfac
mechan
forc
fluid
flow
biochem
gradient
organsonchip
shown
reproduc
complex
integr
organlevel
respons
pathogen
inflammatori
cytokin
well
nanoparticl
pharmaceut
also
effect
recapitul
diseas
state
complex
pathophysiolog
respons
mechan
activ
organsonchip
popul
human
cell
therefor
promis
provid
predict
model
provid
lowercost
altern
anim
clinic
studi
diseas
model
drug
test
safeti
applic
discuss
follow
organsonchip
aim
recreat
complex
dynam
state
live
cell
function
within
nativ
human
organ
includ
interact
substrat
extracellular
matrix
tissuetissu
interfac
mechan
forc
immun
cell
blood
compon
biochem
microenviron
critic
lung
health
diseas
ecm
noncellular
compon
tissu
provid
structur
scaffold
biochem
biomechan
support
surround
cell
lung
organ
ecm
give
tissu
physic
mechan
properti
contribut
tissu
develop
morpholog
function
influenc
cell
shape
cellcel
interact
lung
ecm
influenc
fundament
process
includ
cell
signal
pathway
cell
shape
function
cytoskelet
organ
differenti
organogenesi
wound
heal
ecm
composit
specif
organ
also
uniqu
differ
region
tissu
lung
rel
soft
tissu
elast
modulu
rang
kpa
alveolar
ecm
compos
mix
collagen
iii
iv
v
laminin
fibronectin
elastin
wherea
ecm
larg
airway
includ
collagen
ii
cartilag
v
laminin
fibronectin
extens
ecm
remodel
implic
mani
physiolog
pathophysiolog
process
wound
heal
pulmonari
fibrosi
therefor
ecm
composit
use
model
lung
must
care
select
depend
region
diseas
state
one
seek
model
lung
ecm
scaffold
modul
cellular
function
shape
tissu
architectur
precis
compartment
lung
cell
popul
cell
behavior
also
determin
constant
interact
neighbor
cellular
compart
interact
mediat
direct
celltocel
contact
exampl
airway
epitheli
cell
fibroblast
fibrosi
alveolar
macrophag
alveolar
epitheli
cell
health
diseas
addit
cellular
interact
also
leverag
solubl
factor
epithelialendotheli
cross
talk
influenza
virusinduc
cytokin
storm
endotheli
influenc
epitheli
differenti
mesenchym
cell
influenc
epitheli
develop
celltocel
cross
talk
modul
tissu
growth
differenti
cell
activ
mediat
recruit
immun
cell
inflamm
multi
cell
type
interact
also
recapitul
organsonchip
instanc
cocultur
differenti
human
primari
airway
epitheli
cell
endothelium
close
proxim
result
crosscommun
tissu
follow
treatment
proinflammatori
stimulu
similarli
stimul
epithelium
proinflammatori
agent
result
activ
underli
endothelium
indic
overexpress
adhes
molecul
eselectin
despit
extens
studi
magnitud
natur
mechan
forc
experienc
lung
epitheli
cell
develop
breath
movement
diseas
state
still
well
understood
remain
object
intens
research
admit
normal
breath
movement
lung
undergo
dynam
deform
estim
caus
stretch
distens
basement
membran
deep
inspir
may
induc
stretch
distens
bronchoconstrict
eg
asthma
patient
compress
forc
act
part
airway
wall
mechan
forc
strongli
influenc
lung
cell
includ
effect
growth
repair
surfact
releas
injuri
inflamm
well
tissu
develop
fetal
adult
stage
addit
mechan
forc
influenc
cell
function
develop
includ
shear
stress
induc
bidirect
air
flow
lumen
conduct
airway
blood
flow
capillari
endotheli
cell
abl
sens
adapt
variat
bloodflow
vascular
wall
serv
interfac
blood
tissu
respond
hemodynam
cue
physiolog
shear
stress
act
vascular
wall
show
modul
gene
express
cell
morpholog
cell
metabol
endotheli
cell
organsonchip
offer
possibl
appli
control
physiolog
biomechan
forc
includ
breath
movement
shear
stress
result
air
blood
flow
cell
experi
vivo
biochem
surround
cell
compos
element
secret
transport
tissu
includ
growth
factor
hormon
dissolv
gase
small
molecul
salt
nutrient
lung
biochem
mediat
central
process
rang
tissu
develop
homeostasi
inflamm
injuri
resolut
lung
cell
also
play
signific
role
metabol
xenobiot
endogen
hormon
serotonin
lead
degrad
well
activ
import
biolog
properti
xenobioticmetabol
cytochrom
enzym
express
bronchial
bronchiolar
epithelium
club
cell
type
ii
alveolar
cell
alveolar
macrophag
human
lung
activ
environment
chemic
modifi
cell
biochem
microenviron
contribut
patholog
cancer
copd
express
activ
enzym
part
determin
epitheli
differenti
indic
need
appropri
cellular
differenti
model
organsonchip
offer
possibl
accur
control
region
tempor
biochem
microenviron
cell
control
perfus
growth
medium
gase
circul
resid
immun
cell
key
effector
inflamm
play
central
role
pathogenesi
resolut
respiratori
diseas
togeth
airway
epitheli
cell
lung
resid
circul
immun
cell
dendrit
cell
macrophag
initi
orchestr
immun
respons
abil
perfus
fluid
organsonchip
allow
dynam
suppli
nutrient
gase
also
enabl
perfus
immun
cell
physiolog
condit
shear
stress
experienc
within
microvessel
uniqu
featur
enabl
visual
real
time
monitor
interact
freshli
isol
circul
immun
cell
lung
endotheli
epitheli
cell
whole
human
blood
also
perfus
organsonchip
exampl
thrombot
event
model
util
assess
drug
deliveri
toxic
efficaci
field
organsonchip
deriv
miniatur
total
chemic
analysi
system
microscal
chemic
platform
directli
inspir
develop
miniatur
effort
electron
industri
second
half
twentieth
centuri
fig
later
regroup
name
labonachip
system
integr
fluidic
microsystem
singl
platform
perform
sever
step
chemic
assay
origin
system
contain
live
compon
ad
live
cell
facilit
new
method
fabric
microscal
fluidic
channel
establish
altern
fuse
silica
capillari
specif
organsonchip
emerg
converg
cellular
micropattern
method
design
control
cell
shape
function
earli
miniatur
system
electrophoresi
microengin
cellular
system
initi
call
cell
chip
illustr
merger
cell
biolog
microfabr
method
adapt
comput
microchip
industri
recent
denomin
organsonchip
impli
model
complex
physiolog
organlevel
function
microfabr
biochip
howev
place
silicon
organsonchip
typic
made
hydrogel
silicon
elastom
call
poli
dimethylsiloxan
pdm
play
central
role
organsonchip
sudden
popular
pdm
offer
numer
mechan
chemic
advantag
tradit
microengin
materi
glass
silicon
first
pdm
rel
inexpens
compar
silicon
allow
cheap
prototyp
pdm
stiff
also
easili
modifi
control
degre
crosslink
polym
chain
enabl
design
soft
stretchabl
surfac
similar
mechan
environ
cell
moreov
sinc
pdm
form
tight
seal
glass
revers
irrevers
bound
plastic
polym
hybrid
devic
contain
rigid
part
construct
importantli
pdm
nontox
easi
work
rapid
prototyp
method
involv
soft
lithographi
replica
mold
permit
creation
inexpens
devic
complex
flow
channel
design
final
pdm
ga
permeabl
biocompat
optic
clear
make
particularli
well
suit
grow
live
cell
enclos
fluidic
microchannel
monitor
behavior
use
variou
type
light
microscopi
face
promis
challeng
tissu
engin
notabl
need
cellular
scaffold
blood
perfus
engin
vitro
tissu
research
midnineti
earli
start
adapt
microfabr
approach
cultur
human
cell
engin
human
tissu
earli
attempt
cellular
micropattern
use
pdm
microchannel
seal
tissuecultur
dish
support
align
perfus
growth
fibroblast
later
microfluid
design
model
incorpor
blood
capillarylik
channel
support
cultur
human
endotheli
cell
quickli
follow
cell
type
includ
liver
muscl
bone
brain
gut
kidney
parallel
interconnect
cultur
chamber
contain
cell
deriv
differ
organ
later
call
bodyonchip
system
develop
appli
pharmacolog
studi
henc
organsonchip
origin
develop
solv
perfus
scaffold
challeng
encount
field
tissu
engin
howev
potenti
recapitul
complex
human
organlevel
function
becam
rapidli
evid
led
array
advanc
model
human
lung
tissu
lungonachip
alveolusonachip
small
airwayonachip
applic
includ
studi
lung
cell
growth
injuri
model
alveolar
tissuetissu
interact
inflammatori
process
respons
alveolar
epithelium
drug
mechan
stress
pulmonari
thrombot
event
well
lung
cancer
recent
function
dynam
model
human
airway
compris
welldifferenti
airway
epitheli
cell
airliquid
interfac
develop
importantli
airway
epithelium
support
porou
membran
interact
continu
perfus
pulmonari
microvascular
endothelium
underneath
experi
physiolog
shear
stress
allow
circul
immun
cell
model
leverag
model
human
obstruct
respiratori
diseas
human
viral
infect
test
novel
therapeut
sever
attempt
made
develop
character
function
alveolu
unit
onchip
attempt
sought
recapitul
alveolarcapillari
interfac
recreat
boundari
lung
air
sac
capillari
within
microengin
system
major
system
review
reli
similar
chip
design
microengin
chamber
divid
longitudin
two
parallel
channel
flexibl
ecmcoat
porou
membran
recreat
alveolar
interstitium
design
support
growth
human
alveolar
cell
line
primari
epitheli
cell
airliquid
interfac
human
pulmonari
microvascular
endotheli
cell
hmvec
umbil
vein
endotheli
cell
huvec
line
opposit
side
membran
expos
laminar
flow
cultur
medium
use
elast
materi
membran
chip
hous
enabl
linear
cyclic
stretch
recreat
motion
breath
lung
influenc
cell
behavior
system
appli
replic
diseas
lung
investig
mechan
stress
cell
damag
explor
immun
cell
recruit
extravas
test
drug
efficaci
toxic
first
alveolusonachip
origin
call
lungonachip
use
recapitul
complex
physiolog
mechan
diapedesi
circul
human
primari
neutrophil
follow
stimul
alveolar
epithelium
infect
strain
e
coli
diseas
model
bacteri
infect
lung
endothelium
situat
underneath
alveolar
epithelium
becom
activ
indic
rapid
increas
express
adhes
molecul
promot
adhes
extravas
perfus
neutrophil
organsonchip
made
pdm
transpar
polym
whole
physiolog
process
observ
real
time
high
resolut
microscopi
similarli
lungonachip
recapitul
silica
nanoparticleinduc
toxic
uncov
critic
role
breath
motion
product
reactiv
oxygen
speci
ro
well
cellular
uptak
nanoparticl
transport
across
cell
layer
vascular
channel
anoth
applic
origin
lungonachip
includ
replic
human
pulmonari
edema
lung
toxic
shown
induc
limit
pulmonari
vascular
leakag
air
channel
static
condit
wherea
physiolog
breath
motion
significantli
increas
vascular
permeabl
respons
could
attenu
pharmacolog
inhibitor
anoth
model
lung
alveolar
epithelium
onchip
appli
investig
effect
mechan
strain
surfac
tension
propag
airliquid
interfac
cell
death
cell
murin
type
ii
alveolar
epitheli
cell
wherea
first
lungonchip
recapitul
linear
stretch
altern
design
contain
circular
stretchabl
diaphragm
whose
downward
deflect
enabl
stretch
tissu
line
recent
effort
made
increas
chip
physiolog
relev
use
human
primari
alveolar
epitheli
cell
endotheli
cell
instead
cell
line
stucki
et
al
design
anoth
version
alveolusonachip
also
support
cyclic
deform
human
primari
alveolar
epitheli
cell
studi
found
compar
static
condit
cyclic
stretch
affect
barrier
permeabl
increas
metabol
activ
primari
alveolar
epitheli
cell
releas
inflammatori
marker
complex
model
intravascular
thrombosi
util
human
primari
alveolar
epitheli
human
umbil
vascular
endotheli
cell
also
develop
assess
antithromb
therapeut
model
side
vascular
channel
coat
ecm
seed
endotheli
cell
prevent
clot
perfus
human
whole
blood
studi
show
treatment
alveolar
lumen
epitheliumendothelium
cocultur
lipopolysaccharid
lp
found
outer
membran
gramneg
bacteria
trigger
thrombot
event
convers
lp
stimul
endotheli
cell
alon
lead
blood
clot
format
thu
highlight
import
recapitul
tissuetissu
interfac
model
inflammationmedi
thrombosi
model
lung
cancer
also
develop
alveolusonachip
model
featur
epitheliumendothelium
interfac
small
proport
nonsmal
cell
lung
cancer
tumor
cell
alveolar
space
use
investig
influenc
biomechan
microenviron
tumor
cell
growth
migrat
studi
show
cyclic
stretch
limit
tumor
cell
invas
vascular
compart
also
reduc
efficaci
wide
use
class
cancer
drug
tyrosin
kinas
inhibitor
suggest
local
microenviron
cue
may
influenc
cancer
cell
growth
drug
efficaci
base
similar
design
microfabr
techniqu
use
compartment
microfluid
airway
system
later
alveolusonchip
sever
onchip
assay
model
variou
featur
human
airway
health
diseas
recent
develop
instanc
new
small
airwayonachip
recapitul
human
bronchial
bronchiolar
epithelium
support
full
differenti
columnar
pseudostratifi
mucociliari
bronchiolar
epithelium
compos
human
primari
airway
epitheli
cell
isol
normal
diseas
cell
patient
alveolu
model
epithelium
underlin
function
human
pulmonari
microvascular
endothelium
experienc
continu
fluid
flow
human
airway
cell
cultur
onchip
air
liquid
interfac
three
week
reconstitut
vivolik
epithelium
compos
ciliat
cell
physiolog
cilia
beat
frequenc
well
goblet
cell
secret
mucu
lumen
result
robust
mucociliari
clearanc
interestingli
proport
ciliat
goblet
basal
cell
insid
matur
smallairwayonachip
strikingli
similar
found
human
lung
suggest
reconstitut
tissu
close
recapitul
morpholog
function
human
airway
epithelium
tabl
perfus
vascular
channel
recreat
microenviron
enrich
inflammatori
type
helper
cell
observ
allerg
asthma
result
signific
airway
remodel
goblet
cell
hyperplasia
increas
proinflammatori
cytokin
reduct
cilia
beat
frequenc
phenotyp
suppress
follow
incub
tofacitinib
janu
kinas
jak
inhibitor
block
cytokin
signal
therapeut
prescrib
rheumatoid
arthriti
use
primari
airway
cell
deriv
copd
patient
smallairwayonachip
also
leverag
investig
exacerb
copd
measur
human
neutrophil
recruit
activ
endothelium
follow
epitheli
exposur
proinflammatori
stimuli
addit
smallairwayonachip
separ
air
channel
possibl
circul
airborn
pollut
epitheli
chamber
evalu
exampl
respons
epitheli
cell
cigarett
smoke
recent
advanc
airway
model
also
includ
new
onchip
model
viralinduc
asthma
exacerb
deriv
origin
small
airwayonachip
new
chip
support
infect
fulli
differenti
human
airway
epitheli
cell
human
rhinoviru
hrv
high
titer
enabl
immun
cell
diapedesi
pore
membran
stimul
alter
hrvinduc
proinflammatori
interferon
respons
increas
neutrophil
recruit
vascular
wall
respons
pharmacolog
inhibit
antagonist
altern
onchip
system
human
airway
epithelium
includ
tripl
channel
chip
design
addit
compart
contain
fibroblast
insert
epitheli
vascular
channel
configur
howev
far
support
full
differenti
human
primari
airway
epitheli
cell
remain
promis
investig
cross
commun
three
differ
cell
popul
respect
influenc
growth
differenti
addit
includ
fibroblast
may
use
studi
diseas
idiopath
pulmonari
fibrosi
use
markedli
differ
design
approach
nesmith
et
al
built
human
airway
musculatureonachip
consist
ecm
cantilev
actuat
primari
human
bronchial
smooth
muscl
cell
stimul
increas
cantilev
curvatur
mimick
acetylcholineinduc
hypercontractil
observ
asthmat
respons
could
reduc
rho
kinas
rock
inhibitor
date
everi
lungonchip
system
reli
cancer
immort
cell
line
primari
cell
reconstitut
lung
tissu
vitro
cell
line
cost
effici
enabl
highthroughput
studi
progress
replac
primari
cell
isol
directli
human
anim
tissu
biolog
relev
cancer
otherwis
immort
cell
increasingli
question
primari
cell
offer
number
advantag
compar
cell
line
includ
recapitul
origin
tissu
characterist
abil
differenti
vivolik
tissu
preserv
donor
diseas
phenotyp
increas
predict
human
respons
drug
control
cell
sourc
increas
donor
divers
reflect
natur
divers
human
popul
nonetheless
primari
cell
also
import
drawback
first
primari
cell
usual
limit
lifespan
although
method
prolong
cultur
develop
primari
cell
also
difficult
costli
genet
modifi
transfect
effici
low
hinder
effect
econom
gene
edit
approach
final
primari
cell
divers
also
obstacl
long
term
vitro
studi
cell
patient
hard
obtain
human
stem
cell
hand
overcom
limit
primari
cell
instanc
adult
stem
cell
maintain
indefinit
easi
transform
function
gene
studi
particularli
straightforward
inexpens
stem
cell
singl
patient
also
use
recreat
virtual
cell
type
possibl
exceedingli
valuabl
primari
tissu
difficult
isol
alveolar
epitheli
cell
stem
cell
also
advantag
autolog
cocultur
system
ie
cell
obtain
patient
need
instanc
insur
compat
cultur
epitheli
cell
togeth
therefor
import
consid
replac
primari
cell
organsonchip
stem
cell
either
differenti
cultur
stem
cell
onchip
directli
seed
organoid
insid
chip
furthermor
combin
organsonchip
stem
cell
technolog
would
potenti
enabl
featur
current
miss
lung
organoid
stem
cellbas
system
recapitul
dynam
physicochem
stem
cell
nich
access
lumin
vascular
compart
dynam
immun
cell
circul
control
applic
physiolog
mechan
cue
tabl
lung
cell
deriv
human
pluripot
stem
cell
psc
particularli
human
embryon
stem
cell
esc
induc
pluripot
stem
cell
ipsc
hold
great
potenti
build
advanc
vitro
model
human
lung
tissu
understand
lung
physiolog
diseas
numer
attempt
made
gener
airway
distal
lung
epitheli
cell
human
psc
recent
undertak
gain
signific
traction
initi
studi
first
report
effici
embryon
induct
mesoderm
ectoderm
lineag
howev
matur
third
endoderm
germ
layer
remain
limit
recreat
posterior
endoderm
cell
deriv
give
rise
organ
liver
intestin
pancrea
becam
possibl
earli
anterior
foregut
endoderm
induct
lead
lung
tissu
achiev
recent
key
studi
eventu
elucid
mechan
permit
stem
cell
differenti
lungspecif
endoderm
precursor
thu
lead
effect
strategi
esc
ipsc
gener
lung
epitheli
cell
basic
protocol
gener
lung
progenitor
cell
esc
ipsc
vitro
accomplish
direct
differenti
process
vivo
tissu
development
stage
mimick
use
control
sequenc
endogen
signal
factor
fig
pluripot
stem
cell
first
direct
definit
endoderm
activina
simul
follow
anterior
foregut
endoderm
afe
induct
dual
inhibit
bone
morphogen
protein
bmp
transform
growth
factor
signal
pathway
follow
afe
establish
ventral
pattern
step
need
mirror
morphogenesi
endoderm
trachea
lung
bud
eventu
emerg
ventral
afe
ventral
larg
achiev
wnt
bmp
retino
acid
fibroblast
growth
factor
fgf
signal
yield
cell
express
transcript
factor
major
marker
lung
epitheli
lineag
addit
neural
thyroid
tissu
fate
popul
cell
consid
primordi
lung
epitheli
progenitor
abl
differenti
proxim
airway
distal
lung
bud
lineag
primarili
defin
express
respect
termin
differenti
direct
pathway
signal
modif
determin
specif
set
marker
method
tabl
comparison
structur
function
human
airway
epithelium
vivo
human
airwaychip
valu
human
airway
report
valu
airwaychip
report
human
airway
airway
chip
sd
use
specif
proxim
airway
distal
alveolar
progenitor
discuss
next
paragraph
past
three
year
notabl
progress
made
use
lung
progenitor
gener
human
alveolar
epitheli
cell
leverag
strategi
maintain
human
primari
cell
combin
glucocorticoid
growth
factor
camp
effector
dexamethason
ibmx
collect
known
dcik
shown
induc
alveolar
matur
activ
pka
cdpcholin
pathway
upregul
lamellar
bodi
surfact
product
atii
cell
recogn
marker
distal
alveolar
epithelium
includ
surfact
protein
c
sftpc
surfact
protein
b
sftpb
atii
cell
podoplanin
caveolin
aquaporin
primarili
defin
ati
cell
stimul
two
dimension
cultur
differenti
psc
grow
dcik
wnt
activ
lead
express
ati
atii
marker
matur
phenotyp
characterist
lamellar
bodi
function
surfact
uptak
capabl
similarli
psc
spheroid
cultur
also
induc
cell
matur
alveoli
epithelium
interestingli
cocultur
human
fetal
lung
fibroblast
stimul
dcik
yield
atii
specif
marker
lamellar
bodi
format
although
function
matur
confirm
function
lamellar
bodi
bodipylabel
sftpb
uptak
later
shown
first
gener
psc
lung
bud
organoid
follow
matrigel
cultur
wnt
activ
kgf
ra
place
dcik
atii
marker
found
abund
protocol
ati
marker
minim
express
advanc
matur
atii
cell
character
capac
lamellar
bodi
process
surfact
protein
produc
dipalmitoylphosphatidylcholin
dppc
surfact
phospholipid
demonstr
matur
cell
matrigel
dcik
tempor
modul
wnt
activ
remark
matur
form
sftpb
sftpc
could
also
detect
lamellar
bodi
consist
lategest
primari
fetal
atii
cell
longterm
expans
alveolar
epitheli
cell
challeng
distal
lung
cell
cultur
recent
achiev
use
organoid
approach
refin
differenti
sequenc
afe
induct
sequenc
differ
previou
protocol
close
mimick
distal
tip
cell
microenviron
precondit
step
wnt
activ
daptmedi
notch
inhibit
plu
kgf
supplement
result
sftpc
gene
express
similar
level
found
fetal
lung
cell
matur
use
dcik
organoid
cocultur
fibroblast
interestingli
cocultur
fetal
lung
fibroblast
line
result
sftpc
express
cell
though
extrem
variabl
rang
wherea
incorpor
dermal
fibroblast
line
show
sftpc
induct
passag
proport
atii
cell
cultur
increas
approxim
atilik
cell
also
present
notabl
induct
sftpc
express
also
achiev
fibroblastfre
cultur
use
dcik
plu
rock
inhibit
wnt
activ
inhibit
albeit
lower
effici
protocol
proxim
airway
differenti
also
advanc
past
year
differenti
psc
airway
epitheli
cell
achiev
spheroid
cultur
use
kgf
wnt
agonist
notch
inhibit
recent
modifi
wnt
signal
direct
differenti
strategi
effici
induc
proxim
fate
potenti
explain
previou
studi
encount
difficulti
maintain
airway
epitheli
marker
cultur
suppress
wnt
signal
ventral
afe
promot
proxim
fate
led
epitheli
cell
express
classic
marker
club
cell
goblet
cell
keratin
basal
cell
promot
cilia
develop
airway
notch
inhibit
organoid
airliquid
interfac
cultur
produc
motil
multicili
cell
character
acetyl
alphatubulin
stain
anoth
protocol
use
airliquid
interfac
cultur
stimul
gener
matur
polar
epitheli
layer
motil
cilia
mucu
could
observ
apic
surfac
shown
scaffold
microenviron
ipscderiv
lung
progenitor
major
determin
achiev
matur
airway
epitheli
phenotyp
shown
use
human
ipscderiv
lung
organoid
provid
bioartifici
scaffold
transplant
mous
epididym
fat
pad
eight
week
follow
transplant
airwaylik
structur
observ
organoid
cultur
transplant
scaffold
longterm
expans
ipscderiv
airway
epitheli
cell
may
possibl
incorpor
find
human
primari
cell
cultur
specif
inhibit
signal
pathway
recent
found
enabl
longterm
expans
primari
airway
basal
cell
inhibit
termin
differenti
promot
selfrenew
pathway
may
also
util
improv
proxim
psc
lung
cultur
trace
respiratori
development
path
provid
major
insight
lung
differenti
yet
major
knowledg
lung
develop
stem
rodent
studi
due
limit
avail
human
sampl
recent
new
studi
conduct
examin
human
lung
develop
use
variou
gestat
week
human
fetal
lung
genet
transcriptom
mous
lung
develop
found
remark
similar
human
differ
may
help
identifi
target
develop
better
strategi
advanc
human
lung
model
instanc
lung
bud
tip
signal
associ
sonic
hedgehog
shh
mous
yet
indian
hedgehog
ihh
found
express
human
tip
addit
human
pseudoglandular
tip
found
initi
express
rather
sole
interestingli
tip
cell
use
success
stem
cell
form
organoid
without
mesenchym
cell
convent
fgf
wnt
bmp
signal
modif
despit
progress
recapitul
vivo
development
pathway
lung
differenti
mani
signal
mechan
still
requir
investig
instanc
incorpor
wnt
signal
inhibit
earlier
combin
bmp
inhibit
increas
express
suggest
ventral
pattern
may
begin
afe
addit
util
sonic
hedgehog
shh
signal
promot
afe
express
success
albeit
suboptim
effici
studi
indic
fgf
signal
may
dispens
lung
specif
highlight
need
explor
essenti
time
fgf
signal
current
differenti
protocol
effect
esc
ipsc
sourc
high
induct
effici
remain
one
major
challeng
direct
differenti
strategi
result
heterogen
popul
cell
effici
wide
rang
outcom
led
question
lung
origin
marker
recent
confirm
addit
tool
purifi
lung
progenitor
cell
could
ultim
provid
necessari
suppli
vitro
applic
recent
accomplish
discoveri
highli
specif
cell
surfac
marker
carboxypeptidas
cpm
marker
allow
live
track
sort
result
puriti
cell
differenti
ventral
afe
despit
substanti
progress
advanc
differenti
lung
stem
cell
full
matur
still
key
challeng
paramet
defin
fulli
differenti
epitheli
cell
still
evolv
exampl
demonstr
sftpc
sftpb
gene
express
initi
suffici
claim
atii
cell
differenti
howev
acceler
progress
lung
psc
protocol
strict
metric
consid
reach
ultim
goal
gener
suppli
cell
recapitul
molecular
biochem
phenotyp
function
featur
found
adult
lung
beer
moodley
along
lead
expert
pioneer
lung
field
review
concern
propos
set
standard
specif
alveolar
cell
gener
order
bridg
lung
biolog
stem
cell
develop
summari
claim
termin
atii
cell
matur
cell
need
demonstr
morpholog
similar
vivo
tissu
significantli
matur
surfact
system
characterist
lamellar
bodi
ultrastructur
transmiss
electron
microscopi
function
mainten
repair
barrier
function
selfrenew
regener
transcriptom
analysi
compar
isol
atii
cell
initi
assist
alveolar
stem
cell
develop
call
highli
sophist
techniqu
protocol
lungonchip
platform
may
assist
requir
research
fulli
character
cell
popul
notion
applic
lung
epitheli
gener
paramount
develop
relev
standard
vitro
applic
incorpor
stem
cellderiv
differenti
cultur
lungonchip
model
offer
new
opportun
studi
lung
develop
develop
patientspecif
diseas
model
also
enabl
investig
includ
differ
cell
type
eg
airway
epitheli
endotheli
cell
deriv
donor
within
one
model
close
recreat
spatiotempor
dynam
heterogen
found
lung
lungonchip
model
may
also
use
appropri
differenti
matur
stem
cellderiv
lung
cell
inde
chemic
signal
structur
cue
ecm
addit
cell
type
shown
enhanc
matur
lung
epitheli
psc
implant
injur
mice
scaffold
use
decellular
lung
matrix
multicultur
lung
mesenchym
fibroblast
led
develop
lung
epithelia
fate
furthermor
mani
lung
psc
cultur
system
util
system
creat
advanc
lung
organoid
likewis
lungonchip
model
provid
dynam
microenviron
increas
cellular
complex
factor
known
influenc
stem
cell
differenti
delic
dissoci
stemcel
deriv
organoid
may
possibl
seed
matur
lung
cell
onto
surfac
ecmcoat
porou
membran
form
monolay
within
chip
channel
thu
suppli
cell
microenviron
character
physiolog
ecm
airliquid
interfac
stretch
fluid
shear
also
allow
introduc
ad
complex
vascular
channel
addit
cell
type
endotheli
cell
fibroblast
deriv
ipsc
donor
result
patientspecif
model
fluid
flow
apicalbas
distinct
lungonchip
util
fine
tune
time
distribut
signal
factor
explor
spatiotempor
respons
stimuli
multitud
paramet
organsonchip
technolog
provid
isol
dynam
spatiotempor
heterogen
aspect
vivo
physiolog
hold
great
potenti
fulli
matur
lung
psc
advanc
vitro
lung
model
human
microengin
system
organsonchip
aim
provid
addit
insight
pathogenesi
human
tissu
enabl
predict
drug
efficaci
safeti
physiolog
relev
context
benefit
clearli
establish
combin
organsonchip
human
stem
cell
cell
type
come
donor
would
offer
opportun
test
compound
correct
patient
specif
phenotyp
associ
defin
genotyp
gene
mutat
thu
creat
predict
platform
field
person
medicin
offer
complementari
advantag
model
base
anim
immort
primari
cell
matur
potenti
genet
stabil
embryon
stem
cell
esc
remain
superior
tissuederiv
induc
pluripot
stem
cell
ipsc
present
key
advantag
esc
includ
renew
suppli
patientspecif
cell
individu
acquir
genet
lung
diseas
first
lung
diseasespecif
ipsc
line
gener
includ
line
individu
cystic
fibrosi
antitrypsin
defici
two
common
monogen
lung
diseas
immedi
research
applic
diseasespecif
cell
line
includ
probe
rel
contribut
somat
acquir
versu
genet
risk
factor
genet
engin
induc
repair
put
diseasecaus
mutat
comparison
tissu
deriv
patient
healthi
rel
studi
diseas
patholog
differ
genet
background
respons
drug
direct
consequ
clinic
research
immin
stem
cell
deriv
specif
patient
analysi
respons
variou
stimuli
drug
predict
individu
patient
respons
exampl
compound
improv
specif
function
model
use
ipsc
deriv
patient
result
may
achiev
patient
convers
advers
drug
effect
identifi
human
ipscderiv
tissu
specif
genet
background
might
predict
drug
failur
clinic
trial
subset
patient
monocultur
ipsc
suitabl
investig
monogenet
diseas
complet
penetr
welldefin
cellular
phenotyp
caus
mutat
cellautonom
diseas
cystic
fibrosi
cell
mutat
cystic
fibrosi
transmembran
conduct
regul
cftr
gene
impair
chlorid
ion
transport
cell
express
cftr
howev
integr
multipl
cell
type
immun
cell
dynam
mechanochem
environ
organsonchip
technolog
provid
abil
also
studi
noncellautonom
diseas
asthma
environment
agent
concert
airway
immun
cell
gener
divers
phenotyp
lastli
lungonchip
system
combin
ipsc
could
facilit
research
rare
pulmonari
diseas
preclin
diseas
model
follow
discuss
diseas
might
benefit
stem
cellbas
lungonchip
system
provid
tangibl
exampl
specif
research
question
outlin
could
studi
lungonchip
model
cystic
fibrosi
similar
approach
relev
diseas
discuss
mutat
cftr
gene
caus
cystic
fibrosi
human
debilit
diseas
character
persist
airway
infect
perman
damag
lung
result
chang
chlorid
ion
transport
mucu
rheolog
inflamm
bacteri
adher
past
year
tremend
progress
allevi
symptom
even
treat
underli
molecular
caus
diseas
lead
signific
increas
life
expect
advanc
would
imposs
without
develop
host
preclin
assay
anim
tradit
cell
cultur
model
howev
remain
lack
suitabl
model
system
certain
mechan
includ
predomin
caus
pulmonari
declin
cf
patient
infect
biofilmform
phenotyp
pseudomona
aeruginosa
emerg
cf
lung
mice
delet
cftr
gene
develop
spontan
lung
diseas
chronic
bacteri
infect
seen
human
unlik
human
cftr
mutant
mice
appear
altern
chlorid
ion
channel
compens
dysfunct
transport
cftr
recent
develop
pig
ferret
model
cf
allevi
limit
shown
recapitul
key
aspect
cf
human
includ
persist
bacteri
infect
lung
howev
anim
model
replic
highli
specif
associ
p
aeruginosa
seen
human
patient
unlik
support
genotypephenotyp
studi
mutant
cftr
allel
known
impair
synthesi
traffick
stabil
andor
ion
gate
function
cftr
human
organsonchip
whose
vascular
interstiti
flow
channel
support
control
addit
circul
resid
immun
cell
well
bacteria
promis
new
avenu
studi
interact
microb
epithelium
immun
system
among
mani
applic
system
could
shed
light
develop
suspend
biofilm
p
aeruginosa
typic
form
affect
patient
recruit
respons
polymorphonuclear
leukocyt
pmn
biofilm
role
phagocytosi
neutrophil
extracellular
trap
net
neutrophil
microvesicl
clear
fail
clear
p
aeruginosa
potenti
contribut
patientspecif
cftrdefect
pmn
enabl
chronic
infect
fig
cf
character
heterogen
therapeut
respons
rate
interpret
clinic
trial
problemat
suggest
person
treatment
requir
base
appropri
endpoint
biomark
recent
cftrdepend
swellingrespons
stemcel
deriv
gut
organoid
use
bioassay
probe
diseas
phenotyp
differ
cftr
mutat
screen
mutationspecif
efficaci
cftrrestor
compound
fluoresc
signalbas
assay
enabl
phenotyp
profil
measur
cftrmediat
conduct
stemcel
deriv
lungonchip
model
augment
effort
enabl
measur
lungspecif
function
mucociliari
transport
clinic
relev
endpoint
transepitheli
potenti
differ
inflamm
marker
addit
identifi
new
biomark
sensit
classifi
diseas
phenotyp
detect
drug
respons
could
probe
exampl
much
function
cftr
need
present
normal
mucociliari
clearanc
fig
anoth
potenti
applic
lungonchip
model
probe
pharmacokinet
pharmacodynam
treatment
cystic
fibrosi
patient
inhal
antibiot
cftr
modul
fig
cftr
modul
demonstr
direct
repair
malfunct
protein
partli
restor
normal
lung
function
howev
treatment
requir
continu
pharmacolog
intervent
henc
great
hope
place
restor
therapi
would
bring
longerlast
relief
recent
genom
edit
technolog
use
restor
normal
function
cftr
intestin
stem
cell
organoid
demonstr
power
potenti
system
test
human
gene
therapi
moreov
rnaedit
strategi
common
cf
mutat
success
complet
phase
trial
extend
limit
function
readout
provid
organoid
lungonchip
model
use
gaug
improv
tissuewid
function
mucociliari
clearanc
transepitheli
conduct
rang
pediatr
lung
diseas
due
mutat
gene
encod
surfact
protein
spc
spb
factor
requir
surfact
traffick
caus
surfact
defici
mous
model
gener
gene
delet
tend
recapitul
subset
clinic
spectrum
observ
human
popul
like
differ
lung
physiolog
therapi
develop
thu
far
stemcel
base
vitro
model
human
lung
develop
provid
new
system
studi
etiolog
pathogenesi
pediatr
congenit
lung
diseas
might
lead
novel
therapeut
approach
chronic
obstruct
lung
diseas
copd
asthma
preval
chronic
respiratori
diseas
worldwid
rank
among
top
condit
caus
disabl
global
condit
engend
respiratori
distress
chronic
inflamm
lung
thought
result
environment
exposur
genet
suscept
individu
symptom
exacerb
airborn
particl
viral
bacteri
infect
airway
current
mani
treatment
option
manag
sever
asthma
copd
howev
treatment
reduc
diseas
progress
advanc
research
plethora
model
system
develop
multipl
decad
rang
simpl
model
use
human
cell
eg
bronchial
epitheli
cell
fibroblast
monoor
cocultur
whole
tissu
explant
biopsi
muscl
strip
bronchial
ring
vivo
studi
anim
human
platform
cover
substanti
ground
addit
dynam
perfus
patientspecif
microtissu
could
help
dissect
contribut
environment
factor
genet
predisposit
acquir
suscept
fact
anim
model
natur
develop
asthma
even
render
sensit
antigen
fail
recapitul
aspect
human
pathogenesi
like
due
wellknown
differ
airway
physiolog
anatomi
immunolog
anim
human
instanc
secretori
goblet
cell
increas
size
number
copd
asthmat
airway
patholog
hyperplasia
like
mediat
notch
signalingdirect
differenti
basal
cell
stem
cell
larg
airway
toward
secretori
fate
mice
howev
exhibit
much
lower
abund
goblet
cell
human
therefor
provid
good
model
develop
homeostasi
goblet
cell
healthi
diseas
human
lung
tradit
cell
cultur
model
use
airway
epitheli
cell
asthmat
mimick
asthma
expos
normal
epitheli
cell
asthmaassoci
cytokin
help
reveal
role
inflamm
innat
immun
system
asthma
howev
spatiotempor
dynam
process
easili
studi
either
static
cultur
anim
system
also
origin
patholog
inflammatori
respons
might
found
development
event
humanor
even
patientspecif
utero
fetal
program
gene
express
involv
lung
develop
signal
microbiom
critic
postnat
time
window
thought
promot
immun
toler
human
primari
cell
model
airway
demonstr
new
avenu
toward
address
question
vitro
futur
human
stemcel
base
lungonchip
model
support
dynam
interact
circul
immun
cell
essenti
asthma
copd
pathogenesi
could
model
inflamm
exacerb
lead
evalu
new
therapi
treatment
option
pulmonari
fibrosi
normal
parenchym
tissu
gradual
replac
fibrot
tissu
result
scar
result
function
impair
pulmonari
fibrosi
may
develop
secondari
diseas
autoimmun
disord
hypersensit
pneumon
idiopath
pulmonari
fibrosi
ipf
develop
without
known
caus
although
identif
diseasespecif
mutat
subset
exampl
applic
lungonchip
diseas
model
small
airway
epithelium
deriv
stem
cell
cystic
fibrosi
patient
use
studi
univers
cystic
fibrosi
diseas
mechan
well
role
specif
cftr
mutat
within
context
dynam
microenviron
bloodmucusair
interfac
exampl
chip
use
studi
interact
pmn
biofilmproduc
bacteria
p
aeruginosa
antibiot
treatment
b
sensit
patientspecif
new
establish
marker
lung
function
includ
transepitheli
potenti
differ
mucociliari
clearanc
biomark
inflamm
c
efficaci
deliveri
action
drug
treatment
cystic
fibrosi
patient
cftr
modul
antibodi
patient
clear
evid
genet
predisposit
ipf
particular
sever
form
pulmonari
fibrosi
progress
declin
lung
function
caus
death
us
american
european
year
date
therapi
avail
revers
diseas
process
recent
year
two
pharmacotherapeut
agent
pirfenidon
nintedanib
develop
halt
diseas
progress
howev
use
drug
associ
advers
effect
precis
diseas
mechan
still
unknown
believ
myofibroblast
fibrosi
progenitor
cell
respons
fibrot
architectur
remodel
lung
alter
mucociliari
properti
could
also
contribut
diseas
process
reduc
clearanc
noxiou
agent
epithelium
sever
genet
polymorph
mutat
predispos
ipf
fibrot
process
initi
sustain
remain
unclear
partli
good
mous
model
diseas
exist
lead
poor
preclin
clinic
translat
extens
clinic
trial
failur
patientspecif
vitro
model
human
alveolar
epithelium
urgent
need
help
elucid
pathogenesi
role
genet
predisposit
environment
exposur
determin
diseas
penetr
specif
onchip
model
compris
differ
cell
type
alveolar
epithelium
ideal
patient
recapitul
cross
talk
alveolar
epitheli
cell
surround
fibroblast
could
reveal
unknown
mechan
pathogenesi
lead
new
therapeut
target
addit
abil
test
influenc
physiolog
mechan
stretch
alveolar
cell
vitro
anoth
attract
featur
lungonchip
model
ipf
lung
cancer
lead
caus
cancer
mortal
caus
death
per
year
unit
state
develop
drugresist
tumor
cell
eventu
fatal
metastas
common
despit
aggress
treatment
surgeri
radiat
chemotherapi
longterm
surviv
rate
lung
cancer
patient
remain
low
clearli
new
treatment
strategi
need
approach
elicit
antitumor
immun
respons
antibodybas
immun
checkpoint
receptor
inhibitor
therapi
enhanc
tcell
activ
use
gene
edit
rais
great
hope
howev
mani
case
preclin
efficaci
translat
human
trial
exampl
case
immunolog
respons
correl
surviv
perhap
concern
recent
phase
iiiii
clinic
trial
nearli
studi
fail
due
elev
level
circul
immunosuppress
cytokin
variou
immunolog
checkpoint
human
may
present
anim
model
inde
lack
humanrelev
model
system
tumor
biolog
respons
treatment
immun
respons
observ
quantifi
convent
subcutan
implant
tumor
tissu
mous
model
mimic
organspecif
differ
cancer
growth
respons
drug
observ
clinic
notabl
human
tumor
xenograft
implant
mice
correspond
organ
site
tumor
deriv
better
recapitul
physiolog
tumor
growth
metastasi
result
indic
import
organspecif
microenviron
determin
tumor
biolog
drug
respons
howev
contribut
spatiotempor
dynam
tumororgan
interact
remain
black
box
difficulti
visual
probe
tumor
develop
vivo
convent
vitro
cancer
cultur
hand
amen
real
time
imag
investig
workhors
studi
molecular
mechan
cancer
provid
high
throughput
direct
comparison
experiment
result
wealth
literatur
onlin
data
howev
evid
architectur
real
tumor
might
lead
differ
growth
profil
drug
respons
driven
develop
cancer
cultur
extend
approach
includ
organspecif
microenviron
heterogen
cell
popul
organonchip
model
human
lung
cancer
provid
altern
approach
recapitul
organspecif
microenviron
tissuetissu
interfac
mechanochem
cue
vascular
perfus
potenti
interact
immun
cell
also
enabl
continu
monitor
tumor
evolut
tumororgan
interact
combin
approach
stemcel
deriv
tumor
tissu
could
improv
translat
efficaci
data
preclin
test
clinic
aid
develop
patientspecif
therapi
treatment
strategi
overcom
tumor
drugresist
respiratori
infect
lung
viral
bacteri
sourc
major
caus
human
mortal
worldwid
third
stroke
cardiovascular
diseas
lower
respiratori
infect
constitut
deadli
communic
diseas
caus
million
death
tuberculosi
bacteri
diseas
togeth
influenza
well
diseas
caus
respiratori
syncyti
virus
human
metapneumoviru
parainfluenza
viru
adenovirus
coronavirus
caus
life
threaten
condit
healthi
peopl
even
otherwis
harmless
infect
caus
complic
patient
preexist
lung
diseas
asthma
copd
bronchiectasi
cystic
fibrosi
primari
immunodefici
condit
alter
immunolog
mechan
microbi
invas
suscept
infect
well
onset
durat
sever
symptom
control
dynam
patientspecif
hostmicrob
interact
addit
rise
antibiot
resist
contribut
difficulti
develop
effect
treatment
lung
homeostasi
reli
fine
regul
balanc
immun
toler
toward
innocu
exogen
particl
continu
enter
lung
one
hand
defens
mechan
infecti
agent
hand
imbal
immun
homeostasi
lung
lead
exagger
inflammatori
respons
allergi
cytokin
storm
follow
viral
infect
lead
extens
tissu
damag
respiratori
infect
pathogenesi
larg
mediat
interact
infect
tissu
host
immun
system
includ
lung
resid
circul
immun
cell
vitro
system
enabl
studi
isol
immun
cell
epitheli
cell
static
condit
human
lungonchip
model
dynam
fluidic
system
offer
unpreced
possibl
investig
interact
lung
endothelium
epithelium
abil
flow
immun
cell
dynam
fashion
lung
capillari
uniqu
featur
leverag
dissect
individu
role
infiltr
immun
cell
lung
infect
probe
underli
diseas
mechan
identifi
new
therapeut
target
facilit
vaccin
develop
diseas
phenotyp
also
modul
subtl
interact
patient
resid
immun
cell
exampl
pathogenesi
tuberculosi
caus
bacterium
mycobacterium
tuberculosi
involv
modif
core
cell
signal
pathway
immun
cell
differ
patientspecif
immun
cell
respons
may
explain
respons
infect
highli
variabl
patient
henc
develop
novel
hostdirect
therapi
well
understand
mechan
diseas
onset
progress
tuberculosi
would
benefit
patientspecif
vitro
model
dynam
interact
bacteria
lung
cell
immun
system
preclin
drug
discoveri
develop
process
involv
test
drug
safeti
efficaci
pharmacodynam
pharmacokinet
includ
drug
absorpt
distribut
metabol
excret
well
potenti
drugdrug
interact
lung
toxic
also
aris
inhal
airborn
substanc
prenat
exposur
blood
born
chemic
reason
previous
address
anim
model
particularli
rodent
limit
abil
predict
human
respons
point
opportun
use
stemcel
base
lungonchip
advanc
field
drug
candid
induc
specif
advers
effect
lung
lung
may
affect
gener
cytotox
sever
hundr
medic
deliv
variou
rout
known
caus
druginduc
advers
respons
respiratori
complic
clinic
histolog
symptom
often
nonspecif
difficult
diagnos
lungrel
advers
drug
reaction
especi
patient
take
multipl
drug
henc
pulmonari
toxic
estim
approxim
like
underdiagnos
advers
effect
idiosyncrat
due
toxic
reaction
drug
one
metabolit
sinc
lung
metabol
certain
substanc
addit
secondari
mechan
immun
system
respons
caus
damag
exampl
druginduc
interstiti
lung
diseas
dild
common
complic
caus
acut
respiratori
distress
lead
pulmonari
fibrosi
character
prolifer
fibroblast
extens
ecm
deposit
dild
thought
caus
direct
dosedepend
cytotox
bronchial
epitheli
cell
alveolar
capillari
endothelium
also
tcell
mediat
immun
respons
age
sex
exist
lung
diseas
drug
interact
drug
dose
risk
factor
known
correl
phenotyp
dild
druginduc
respiratori
diseas
mechanist
understand
factor
influenc
diseas
onset
progress
lack
human
lungonchip
model
could
help
isol
probe
genet
predisposit
specif
patient
popul
elucid
interdepend
risk
factor
predict
safeti
risk
identifi
safe
drug
dose
regimen
addit
probe
drug
safeti
lungonchip
model
also
attract
rout
toward
improv
vitro
model
inhal
toxicolog
probe
advers
effect
inhal
substanc
origin
environment
occup
extern
sourc
particular
exposur
cigarett
smoke
airborn
nanoparticl
ultrafin
particul
becom
emerg
health
concern
associ
among
advers
health
effect
inflamm
exacerb
preexist
respiratori
diseas
lung
cancer
particleinduc
lung
fibrosi
furthermor
inhal
toxic
gaseou
airborn
substanc
remain
import
caus
lung
injuri
occup
exposur
part
world
chemic
warfar
mani
toxic
gase
mechanist
understand
specif
treatment
option
acut
chronic
injuri
lack
human
vitro
inhal
model
ga
toxic
would
address
unmet
need
vitro
model
inhal
toxic
particularli
challeng
standard
procedur
deliv
airborn
toxin
gase
airliquid
interphas
exist
let
alon
incorpor
effect
breath
flow
dynam
mode
deliveri
flow
dynam
howev
greatli
affect
rel
exposur
time
effect
dose
toxic
safeti
margin
henc
lack
standard
procedur
also
prevent
standard
toxic
dose
assay
inhal
agent
lungonchip
model
present
opportun
address
challeng
deliv
airborn
toxic
particl
gase
spatiotempor
control
manner
enabl
studi
toxic
physiolog
inhal
also
futur
provid
mean
standard
safeti
test
inhal
substanc
lastli
stemcel
base
lungonchip
model
could
also
provid
system
studi
abil
chemic
disrupt
neonat
develop
lung
exampl
known
anim
studi
matern
exposur
nicotin
pass
placenta
accumul
amniot
fluid
caus
alter
postnat
lung
function
overexpress
nicotin
acetylcholin
receptor
collagen
studi
human
embryon
stem
cell
demonstr
direct
modul
differenti
pathway
lung
fibroblast
nicotin
support
hypothesi
lung
matrix
deposit
henc
connect
tissu
mechan
could
alter
postnat
lung
lungonchip
model
recapitul
step
airway
develop
could
enabl
realtim
studi
complex
multicel
type
interact
deposit
ecm
affect
exposur
nicotin
chronic
lung
diseas
avail
treatment
aim
provid
symptomat
relief
rather
cure
underli
diseas
mechan
mani
new
drug
develop
base
diseas
target
identifi
mani
year
ago
clinic
trial
plagu
high
failur
rate
number
recent
trial
shown
promis
fail
later
stage
underli
need
better
understand
patient
phenotyp
preclin
model
greater
relev
reproduc
predict
care
design
scenario
diseas
stage
lungonchip
model
particular
could
help
identifi
preclin
endpoint
translat
clinic
stratifi
diagnosi
therapeut
care
base
molecular
mechan
tailor
treatment
patient
subgroup
design
trial
endpoint
better
predict
drug
efficaci
inde
respiratori
expert
council
rec
global
team
research
clinic
expert
present
recommend
improv
drug
research
develop
airway
diseas
three
human
lungonchip
model
pois
facilit
first
captur
understand
heterogen
airway
diseas
pathophysiolog
clinic
present
airway
diseas
need
redefin
base
molecular
mechan
systemsbiologybas
strategi
particularli
network
analysi
character
variabl
due
patient
patient
differ
due
progress
diseas
variou
stage
categor
diseas
way
could
facilit
design
patientspecif
stagespecif
therapi
advanc
person
respiratori
medicin
simplest
applic
systemsbiologybas
diseas
definit
help
address
question
whether
new
drug
develop
test
broad
diseas
categori
copd
focu
specif
diseas
phenotyp
particular
even
patient
exhibit
similar
symptom
clinic
level
molecular
factor
drive
diseas
progress
differ
vice
versa
stemcel
base
model
provid
platform
reveal
genotypephenotyp
relationship
affect
drug
respons
differ
patient
popul
pharmacogenom
insight
could
inform
design
clinic
trial
determin
inclus
exclus
criteria
patient
assur
optim
drug
target
second
preclin
studi
also
need
take
account
system
manifest
airway
diseas
inflamm
immun
system
respons
link
molecular
tissuelevel
diseas
symptom
well
clinic
endpoint
vascular
lungonchip
model
provid
dynam
environ
allow
control
experiment
access
interact
local
lung
tissu
system
factor
immun
system
compon
even
organ
tissu
final
new
biomark
lung
function
need
translat
experiment
model
clinic
particular
interest
develop
imag
marker
biomark
sensit
differ
stage
airway
diseas
demarc
earlystag
lung
diseas
group
patient
distinct
phenotyp
endotyp
popul
toward
goal
lungonchip
model
provid
system
identifi
dynam
morpholog
solubl
genet
omic
marker
could
integr
clinic
readout
blood
test
biopsi
imag
patientreport
outcom
clinic
endpoint
forc
expiratori
volum
fev
multidimension
diseas
signatur
would
support
design
endpoint
measur
vitro
clinic
directli
relat
diseas
progress
drug
efficaci
inhal
attract
rout
drug
deliveri
larg
surfac
area
adult
good
vascular
thin
alveolar
epithelium
offer
potenti
rapid
absorpt
pharmaceut
either
local
deposit
system
deliveri
also
great
interest
develop
inhal
drug
local
treatment
lung
diseas
includ
pneumonia
howev
accur
pulmonari
drug
deliveri
trivial
task
complex
mechan
chemic
biolog
pharmacokinet
pk
mechan
play
includ
drug
deposit
absorpt
distribut
metabol
variou
clearanc
mechan
first
step
drug
deposit
depend
mostli
fluidmechan
lung
morpholog
breath
pattern
aerosol
veloc
particl
size
densiti
part
dose
reach
target
site
lung
wherea
signific
fraction
remain
inhal
devic
deposit
mouth
throat
due
larg
spatial
scale
involv
understand
predict
initi
drug
deposit
reli
comput
model
perfus
anim
lung
organonchip
model
great
potenti
howev
aid
model
mani
aspect
drug
fate
follow
deposit
differ
region
lung
addit
provid
insight
regionspecif
pharmacodynam
activ
due
vari
target
express
densiti
throughout
lung
specif
pulmonari
absorpt
tissu
blood
circul
occur
deposit
drug
particl
dissolv
surfac
line
fluid
ii
overcom
variou
defens
mechan
lung
clear
inhal
particl
includ
mechan
ie
mucociliari
clearanc
chemic
eg
surfact
lipid
antiproteas
immunolog
eg
phagocytosi
respons
iii
pass
transepitheli
airblood
barrier
passiv
diffus
carriermedi
activ
transport
via
paracellular
transcellular
pathway
iv
withstand
activ
lung
metabol
activ
rel
role
mechan
drug
absorpt
vari
depend
airway
region
exampl
conduct
airway
nasal
caviti
sinus
nasopharynx
oropharynx
larynx
trachea
bronchi
bronchiol
line
ciliat
cell
mucussecret
cell
togeth
enabl
mucociliari
clearanc
inhal
particl
greatli
reduc
bioavail
drug
compound
respiratori
region
hand
compris
total
surfac
area
consist
respiratori
bronchiol
alveolar
duct
alveolar
sac
drug
bioavail
limit
absorpt
transport
across
pulmonari
airblood
barrier
metabol
macrophag
clearanc
complex
lung
morpholog
quantit
character
vivo
interplay
contribut
factor
either
vitro
assay
silico
method
ongo
challeng
exampl
rodent
gener
expos
intratrach
via
noseonli
inhal
henc
result
plasma
pharmacokinet
result
absorpt
differ
region
lung
comput
model
approach
attempt
deriv
pk
paramet
mechanist
base
physicochem
characterist
drug
eg
aqueou
solubl
anatom
physiolog
tissu
properti
altern
clinic
pk
data
mean
statist
correl
approach
limit
preexist
knowledg
data
recent
also
microfluid
approach
studi
dynam
deposit
particl
truescal
cellfre
physic
model
pulmonari
acinu
help
isol
pure
mechan
mechan
stemcel
base
lungonchip
model
could
complement
approach
enabl
empir
measur
pk
paramet
drug
absorpt
cellular
tissu
level
exampl
local
drug
dissolut
could
measur
especi
lipophil
drug
repres
ratelimit
process
pulmonari
absorpt
tempor
dynam
patientspecif
condit
reveal
recapitul
organspecif
barrier
function
endotheli
cell
junction
electr
resist
presenc
specif
membran
transport
metabol
enzym
genotyp
variat
diseas
condit
drugdrug
interact
also
effect
elimin
process
mucociliari
clearanc
pulmonari
bioavail
could
measur
addit
flow
environ
organsonchip
enabl
realist
test
timedepend
effect
builtup
drug
residu
drug
carrier
caus
local
toxic
two
princip
challeng
involv
design
engin
lungonchip
model
suitabl
reproduc
scalabl
research
build
biolog
ie
decid
cell
ecm
element
dynam
microenviron
togeth
enact
desir
structurefunct
relationship
organ
ii
build
chip
hardwar
ie
identifi
materi
geometri
support
studi
mainten
tissu
biolog
time
amen
reliabl
batch
fabric
applic
fig
discuss
great
detail
main
compon
determin
biolog
system
cell
type
sourc
architectur
ecm
composit
distribut
biomechan
forc
flow
shear
tissu
strain
model
system
tissu
compon
mechan
properti
chosen
care
achiev
structurefunct
relationship
interest
without
overli
complexifi
system
could
mask
import
mechan
hinder
reproduc
make
result
harder
interpret
complementari
biolog
compon
chip
geometri
materi
need
chosen
provid
appropri
structur
support
implement
desir
flow
dynam
mechan
forc
support
instrument
tissu
mainten
experiment
readout
ideal
materi
need
nontox
optic
clear
afford
moldabl
machin
nondegrad
cell
cultur
condit
flexibl
allow
stretch
alter
chemistri
fluid
environ
togeth
criteria
difficult
achiev
exampl
discuss
earlier
pdm
materi
choic
mani
proofofconcept
organsonchip
design
howev
despit
advantag
rapid
prototyp
use
sometim
limit
tendenc
absorb
specif
small
hydrophob
pharmaceut
compound
encourag
develop
new
nonabsorb
organsonchip
materi
similarli
chip
geometri
constitut
major
factor
provid
physiologicallyrelev
environ
amen
sampl
organsonchip
current
publish
featur
rather
simpl
flow
circuit
serv
mostli
perfus
ga
exchang
sophist
scenario
contain
inflow
sensor
drug
dispens
could
design
help
design
simul
softwar
routin
done
microfluid
applic
howev
introduc
complex
fluidic
microchannel
network
may
increas
bubbl
format
could
turn
damag
cultur
shear
forc
cell
dri
bubbl
block
medium
perfus
eventu
howev
success
lungonchip
model
achiev
signific
scientif
impact
depend
much
scientif
merit
eas
use
fabric
directli
relat
reproduc
result
across
sampl
experi
user
well
scalabl
experiment
work
provid
suffici
capac
reason
effort
need
direct
toward
achiev
streamlin
chip
manufactur
happen
nonbiolog
microfluid
toward
develop
userfriendli
platform
support
largescal
experiment
work
consid
aspect
togeth
design
chip
seem
daunt
prospect
howev
branch
industri
deal
complex
microengin
system
mechatron
develop
rang
comput
simul
tool
optim
design
fabric
base
desir
usag
goal
past
experi
tool
start
emerg
organsonchip
commun
promis
yet
anoth
technolog
transfer
electron
biolog
microengin
recent
advanc
develop
organsonchip
stem
cell
base
organoid
make
combin
particularli
attract
studi
dynam
process
lung
develop
regener
pathogenesi
well
person
medicin
howev
nowaday
multitud
model
avail
need
note
approach
merit
therefor
essenti
research
adapt
choic
model
base
research
question
logist
consider
thu
far
lungonchip
model
develop
mostli
employ
academ
research
gener
proofofconcept
data
broader
access
technolog
increas
experiment
throughput
enabl
translat
technolog
pharmaceut
industri
clinic
decis
make
meet
high
expect
lungonchip
model
howev
need
care
balanc
continu
increas
biolog
relev
complex
chip
design
one
hand
optim
implement
industri
requir
greater
reproduc
capac
eas
use
hand
meanwhil
patientspecif
cell
alreadi
use
predict
efficaci
drug
clinic
exampl
netherland
health
care
system
cover
evalu
cystic
fibrosi
drug
patientspecif
human
organoid
assess
whether
patient
would
benefit
medic
merg
two
technolog
engin
patientspecif
stemcel
base
lungonchip
model
amplifi
respect
advantag
enabl
design
human
model
predict
efficaci
safeti
drugdrug
interact
clinic
trial
applic
precis
medicin
demand
model
expect
grow
continu
given
current
ban
anim
test
develop
consum
product
like
expand
europ
european
union
direct
north
america
worldwid
given
press
need
predict
preclin
model
drug
discoveri
develop
enabl
applic
howev
new
lungonchip
model
need
held
stringent
uniform
qualiti
control
criteria
formid
challeng
mani
differ
chip
design
current
develop
academ
laboratori
highlight
need
creat
standard
user
guidelin
addit
har
inher
variabl
cell
sourc
one
challeng
balanc
tradeoff
increas
biolog
complex
chip
one
hand
maintain
scalabl
fabric
eas
use
hand
gener
greater
degre
biolog
complex
extend
rang
function
studi
physiolog
relev
might
convers
impair
econom
factor
number
fabric
step
per
sampl
reproduc
result
eas
use
throughput
volum
cell
reagent
need
therefor
slow
gener
adopt
address
hurdl
us
american
fund
agenc
start
initi
toward
consolid
develop
organsonchip
achiev
robust
replic
nation
institut
health
nih
partnership
defens
advanc
research
project
agenc
darpa
fda
recent
pharmaceut
industri
invest
academ
team
compani
develop
organsonchip
technolog
suitabl
industri
applic
initi
promis
address
challeng
discuss
review
current
pace
innov
continu
might
soon
wit
emerg
ideal
human
lung
model
provid
largescal
screen
molecular
level
analysi
cellcel
interact
time
provid
platform
studi
treat
lung
disord
person
medicin
approach
